[Pharmacokinetics of CDDP by the route of administration in patients with ovarian cancer].

CDDP was administered to 36 patients with ovarian cancer by one of three routes: i.v., ip, or ia, and its pharmacokinetics was studied. 1) With an initial dose of 100 mg/body the peak values for blood free-pt were 1.63 +/- 0.78 micrograms/ml (S.D.) in the i.v. group, 0.61 +/- 0.53 micrograms/ml (S.D.) in the ip group, and 1.62 +/- 0.78 micrograms/ml (S.D.) in the ia group. The area under the curve (AUC) was 2.56 +/- 0.72 micrograms.hr/ml (S.D.), 1.84 +/- 0.75 micrograms.hr/ml(S.D.), and 2.70 +/- 0.51 micrograms.hr/ml (S.D.), respectively. 2) The free-pt level of the ascitic fluid in the ip group was 25.3 +/- 28.1 micrograms/ml (S.D.) just after the injection of 100 mg/body. 3) The ovarian tissue level following the initial CDDP dose of 100 mg/body was the highest in the ia group, next highest in the ip group, and lowest in the i.v. group. In some cases, the ovarian tissue level was markedly elevated after repeated ip injections. Deep-middle layer concentrations in ovarian tissue were not so low in the ip group as in the i.v. or ia group. As noted above, the blood free-pt peak was low following ip administration, but the ovarian tissue level was higher following ip administration than following i.v. though lower than following ia administration. These findings suggest that ip administration of CDDP may be useful in treating large tumor masses. Good results are expected particularly following repeated ip therapy, which sometimes provided a markedly high tissue level.